Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03533816 |
Recruitment Status :
Recruiting
First Posted : May 23, 2018
Last Update Posted : March 16, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Myeloid Leukemia Chronic Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndromes | Drug: EAGD T-cell infusion (Phase I) Drug: EAGD T-cell infusion (Expansion) | Phase 1 |
Many patients with hematological malignancies require a bone marrow transplant for curative treatment. A matched sibling donor is optimal but may not be available. Therefore, a partially matched family member (haploidentical) may be a viable alternative. The incidence of graft vs. host disease, however, can become more of a significant, even fatal, factor with partial matches.
T-cells have been shown to be the key player in the post-transplant immune phenomena. The majority of T-cells are composed of alpha beta T-cells with a small minority of gamma delta T-cells, which are known to have the unique ability to kill malignant cells without antigen recognition.
This study proposes to extract, concentrate, and activate gamma delta T-cells from the peripheral blood to provide innate anti-tumor effect with minimal risk of GVHD. Safety and impact and/or the rate of GVHD will be evaluated.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 38 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | This dose escalation study will be conducted in two phases. The first phase will have three cohorts with three recipient/donor pairs at different dose levels for each cohort. The second phase is an expansion cohort at the maximum tolerated dose determined in the first phase. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide |
Actual Study Start Date : | January 31, 2020 |
Estimated Primary Completion Date : | January 2023 |
Estimated Study Completion Date : | January 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: EAGD T-cell infusion (Phase I)
Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
|
Drug: EAGD T-cell infusion (Phase I)
The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
Other Names:
|
Experimental: EAGD T-cell infusion (Expansion)
Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
|
Drug: EAGD T-cell infusion (Expansion)
The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
Other Names:
|
- Phase I - Dose-limiting toxicity (DLT) [ Time Frame: Baseline to Day 30 ]The dose escalation strategy will follow the Food and Drug Administration Guideline for design of early phase clinical trials of cellular therapy products.
- Phase I - Severe acute adverse events following infusion of EAGD T-cells [ Time Frame: Baseline to Day 100 ]Safety of the infusion will be based on the risk of treatment-related severe adverse events as identified in the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) version 4.
- Expansion phase - Rate of acute GVHD [ Time Frame: Baseline to Day 100 ]Monitoring for GVHD is assessed with Grade II-IV adverse events as identified by the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) version 4.
- Expansion phase - Relapse following haploidentical HCT and PTCy with EAGD T-cell infusion [ Time Frame: Baseline to 100 days ]Number of subjects who have acute GVHD by day 100 post-HCT after infusion of EAGD T-cells
- Expansion phase - Non-relapse mortality following haploidentical HCT and PTCy with EAGD T-cell infusion [ Time Frame: Baseline to 100 days ]Number of subjects who have no relapse by day 100 post-HCT after infusion
- Expansion phase - Overall survival following haploidentical HCT and PTCy with EAGD T-cell infusion [ Time Frame: Baseline to 100 days ]Number of subjects who are living by day 100 post-HCT after infusion
- Rate of one-year relapse-free survival (RFS) [ Time Frame: Baseline to one year ]Number of subjects living without relapse of disease after one year following HCT
- Rate of one-year non-relapse mortality (NRM) [ Time Frame: Baseline to one year ]Number of subjects no longer living but not from disease relapse after one year following HCT
- Rate of one-year overall survival (OS) [ Time Frame: Baseline to one year ]Number of subjects living after one year following HCT
- Proportion of subjects with chronic GVHD at one year [ Time Frame: Baseline to one year ]Number of subjects with chronic GVHD after one year following HCT

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The following criteria are used to enroll patients in the study before transplant.
-
Patients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:
- Acute myeloid leukemia [AML] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease
- Chronic myeloid leukemia [CML] in any chronic phase.
- Myelodysplastic syndrome [MDS] with intermediate/high risk features or refractory disease (with bone marrow blast count <10%).
- Acute lymphoblastic leukemia [ALL] in morphologic complete remission with high-risk features or relapsed disease.
- Negative test for donor-specific antibody within 28 days of starting conditioning regimen.
- Age Criteria: 19-65 years.
-
Organ Function Criteria: The following organ function testing should be done within 35 days before study registration.
- Cardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram.
- Pulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected.
- Renal: serum creatinine level to be <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2.
- Hepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN.
- Performance status: Karnofsky performance score (KPS) or Lansky score: ≥80.
- Hematopoietic cell transplant comorbidity index (HCT-CI) <3. Exception may be made on individual cases after discussion with the primary investigator.
- Consent: All patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.
The following criteria are required within 48 hours prior to infusion of the EAGD T cell product.
- Absence of uncontrolled infection with sepsis syndrome (e.g persistent positive blood culture).
- NO hemodynamic instability (due to sepsis or organ dysfunction) or circulatory volume overload.
-
NO clinically significant organ toxicity that are defined as follows:
- Heart failure with subnormal LVEF or clinical fluid overload.
- Elevated serum creatinine or subnormal creatinine clearance (either estimated or measured).
- Elevated total bilirubin ≥1.5 upper normal level (unless indirect hyperbilirubinemia attributed to non-hepatic pathology), or elevated liver enzymes (ALT, AST, ALP) >5 x ULN.
- Hypoxemia requiring oxygen therapy
- NO acute graft versus host disease (any grade).
- Neutrophil engraftment.
Exclusion Criteria:
- Non-compliant patients.
- No appropriate caregivers identified.
- Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).
- Active central nervous system (CNS) neoplastic involvement.
- Morbid obesity with body mass index >35 (borderline cases may be considered on case-by-case basis after discussion with the primary investigator).
- Patients with known allergy to DMSO.
- HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive.
- Pregnant or breastfeeding women.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03533816
Contact: Clinical Trial Nurse Navigator | 913-945-7552 | ctnursenav@kumc.edu |
United States, Kansas | |
University of Kansas Cancer Center | Recruiting |
Westwood, Kansas, United States, 66205 | |
Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu | |
Contact: Joseph McGuirk, M.D. 913-588-6030 jmcguirk@kumc.edu |
Principal Investigator: | Joseph McGuirk, M.D. | University of Kansas Medical Center |
Responsible Party: | Joseph McGuirk, Professor & Division Director, University of Kansas Medical Center |
ClinicalTrials.gov Identifier: | NCT03533816 |
Other Study ID Numbers: |
IIT-2018-Gamma-DeltaTcell |
First Posted: | May 23, 2018 Key Record Dates |
Last Update Posted: | March 16, 2022 |
Last Verified: | March 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Gamma delta T-cells Hematopoietic Stem Cell Transplantation (HCT) Post-transplant Cyclophosphamide (PTCy) |
Expanded/Activated gamma delta (EAGD) Graft versus host disease (GVHD) haploidentical |
Leukemia Leukemia, Myeloid Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive Myelodysplastic Syndromes Neoplasms by Histologic Type Neoplasms Bone Marrow Diseases |
Hematologic Diseases Leukemia, Lymphoid Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Myeloproliferative Disorders |